Eugene Dawson, DO
Cardiovascular Disease · Indian Land, SCNPI 1346282555
Payments from drug & device makers
Across 19 payments — averaging $19.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Irhythm Technologies, Inc.$86
- Abbott$61
- Boehringer Ingelheim$59
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$53
- Medtronic$33
- Scpharmaceuticals Inc.$24
- plus $58 from 4 others
What the payments were for
- Food & beverage$376100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Irhythm Technologies, Inc. | 5 | $86 |
| Abbott | 2 | $61 |
| Boehringer Ingelheim | 2 | $59 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $53 |
| Medtronic | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $24 |
| Amgen | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Boston Scientific | 1 | $14 |
| AstraZeneca | 1 | $13 |
How this compares
$376 in reported general payments places this provider in the 10th percentile of 257 cardiovascular disease providers in South Carolina.
See all cardiovascular disease providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 189 | $222,974 |
| XareltoRivaroxaban | 49 | $63,799 |
| Repatha SureclickEvolocumab | 15 | $9,956 |
| Metoprolol Succinate | 201 | $3,001 |
| Verapamil SrVerapamil Hcl | 17 | $1,826 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 54 | $1,279 |
| Losartan Potassium | 64 | $1,032 |
| Flecainide Acetate | 17 | $971 |
| Valsartan | 11 | $920 |
| Atorvastatin Calcium | 81 | $720 |
| Digoxin | 35 | $710 |
| ClopidogrelClopidogrel Bisulfate | 25 | $492 |
| Rosuvastatin Calcium | 31 | $474 |
| Carvedilol | 59 | $462 |
| Amlodipine Besylate | 88 | $453 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Indian Land
- Brent McLaurinAnderson$1.1M
- Robert BiedermanCharleston$801K
- James MerriamGreenville$728K
- Vipul ShahLancaster$488K
- Arthur EberlyGreenville$438K
- Gregory SanGreenville$429K
- Naresh MoriRock Hill$408K
- Priya KumarGreenwood$351K
- Dev VazGreenville$257K
- William YarbroughCharleston$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.